A clinical briefing on Brimonidine availability in 2026. Prescribing implications, supply chain factors, cost considerations, and tools to help patients access this medication.
As an ophthalmologist, optometrist, or primary care provider who prescribes glaucoma medications, you've likely fielded calls from patients unable to fill their Brimonidine prescriptions. This briefing provides an evidence-based overview of the current supply situation, prescribing considerations, and practical tools to help your patients maintain uninterrupted therapy.
As of Q1 2026, Brimonidine tartrate is not listed on the FDA's drug shortage database. Multiple generic manufacturers — including Apotex, Sandoz, and others — continue to produce brimonidine ophthalmic solution 0.2%. Brand-name Alphagan P (0.1% and 0.15%) also remains available through AbbVie/Allergan.
The patient-reported difficulty in finding Brimonidine is primarily driven by pharmacy-level inventory management rather than upstream manufacturing shortfalls. Contributing factors include:
Brimonidine has not experienced a major documented shortage comparable to drugs like Adderall or Ozempic. However, the broader ophthalmic drug supply chain has faced intermittent disruptions:
The sterile manufacturing requirements for ophthalmic products remain a systemic vulnerability. Facilities producing eye drops must meet stringent cGMP standards, and quality-related shutdowns at any single facility can create temporary ripple effects across the market.
When patients report difficulty filling Brimonidine, consider the following clinical strategies:
If a patient can't find their prescribed strength, consider whether a switch is clinically appropriate:
The 0.2% generic is typically the most findable option. For patients experiencing allergic conjunctivitis with the 0.2% formulation, switching to the Purite-preserved 0.15% Alphagan P — rather than discontinuing brimonidine entirely — may resolve tolerability issues while maintaining IOP control.
When Brimonidine is genuinely unavailable or poorly tolerated, evidence-based alternatives include:
For comprehensive patient-facing information on alternatives, see our guide on alternatives to Brimonidine.
Helping patients locate Brimonidine often requires going beyond writing the prescription. Practical steps include:
Cost barriers can compound availability issues, particularly for uninsured or underinsured patients:
When cost is a primary barrier, prescribing the generic 0.2% formulation — which is therapeutically equivalent and widely covered — is the most pragmatic approach. For patients who need Alphagan P specifically, assist with the co-pay program enrollment.
For more details to share with patients, see how to save money on Brimonidine.
Streamline how your practice handles Brimonidine availability issues:
The glaucoma treatment landscape continues to evolve with sustained-release technologies (e.g., Durysta bimatoprost implant), MIGS procedures, and novel drug delivery systems that may reduce dependence on daily topical medications. However, brimonidine ophthalmic drops will remain a cornerstone of glaucoma management for the foreseeable future.
Proactive inventory monitoring and flexible prescribing — both in terms of formulation strength and therapeutic class — remain the best strategies for ensuring your patients maintain uninterrupted IOP control.
Brimonidine supply in 2026 is stable at the manufacturing level, but pharmacy-level availability gaps continue to affect patients. By leveraging real-time stock-checking tools, maintaining prescribing flexibility across formulations and therapeutic classes, and connecting patients with cost-assistance programs, you can minimize treatment disruptions.
For additional provider resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
